Gensia Sicor Announces Court's Denial of Zeneca's

Motion for Preliminary Injunction Against FDA IRVINE, Calif. (ots-PRNewswire) - Gensia Sicor Inc. (Nasdaq: GNSA) today announced that on Friday, a judge in the U.S. District Court in Baltimore, Maryland denied Zeneca Inc.'s motion for a preliminary injunction against the Food and Drug Administration ("FDA"). The preliminary injunction would have forced the FDA to rescind its approval of Gensia Sicor's generic formulation of Propofol Injectable Emulsion 1% with sodium metabisulfite. "We are not surprised that the court was able to come to a logical decision in this matter by seeing through the fictitious claims made by Zeneca regarding the FDA's alleged failure to adequately address safety issues before approving Gensia Sicor's formulation of propofol," said Michael D. Cannon, president of Gensia Sicor Pharmaceuticals. "We have always maintained that this lawsuit is without merit and is just one more tactic by Zeneca in their quest to prevent a lower-cost alternative to their product from entering the market. "We continue to support the FDA in their defense of this suit and remain confident that their decision will be upheld by the courts," continued Cannon. "In fact, we have already begun production of propofol and have focused our attentions on preparing for a successful commercial launch of propofol in the second quarter of this year." Gensia Sicor Inc. is a vertically integrated pharmaceutical company with proven expertise in the development, manufacturing and marketing of injectable pharmaceuticals and in the production of specialty bulk drug substances utilizing synthesis or fermentation. The company is focused on the worldwide oncology and injectable pharmaceutical markets. Gensia Sicor's commercial pharmaceutical businesses include Gensia Sicor Pharmaceuticals, Inc., a California-based manufacturer and marketer of multisource injectable drugs, SICOR-Societa Italiana Corticosteroidi S.p.A. and Diaspa S.p.A., both of Milan Italy, and Sicor de Mexico, S.A. de C.V. in Toluca, Mexico all which produce specialty bulk drug substances, and Lemery, S.A. de C.V. in Mexico City which manufactures injectable and oral finished multisource drug products. Gensia Sicor's company offices are located in Irvine, CA. This press release contains forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward looking statements, including whether Gensia Sicor's propofol product will have a successful commercial launch, whether that launch will occur in the second quarter, whether Gensia Sicor's propofol product will receive market acceptance and those matters set forth in the risk factors section of Gensia Sicor's filings on Forms 10-K and 10-Q with the Securities and Exchange Commission. These forward looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward looking statements. For more information on the Company, visit Gensia Sicor's new web site at www.gensiasicor.com. News releases are also available at no charge through PR Newswire's News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by Gensia Sicor, call 800-758-5804, extension 354050. Please retain these numbers for future reference. ots Original Text Service: Gensia Sicor Inc. Internet: http://www.newsaktuell.de Contact: Laurie W. Little of Gensia Sicor Inc., 949-455-4879; or Carolyn Bass or Jim Byers, 415-296- 7383, or Patricia Walsh, or Mark Owen, 212-850-5600, all of Morgen-Walke Associates, Inc., for Gensia Sicor Inc. Company News On-Call: http://www.prnewswire.com/comp/354050.html or fax, 800-758-5804, ext. 354050 Web site: http://www.gensiasicor.com Subscribers please note that material bearing the slug "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" slug. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents. PROTEXT